Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript

SA Transcripts 162.34K Followers Follow Roche Holding AG ( RHHBY ) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas September 28, 2026 4:30 AM EDT Company Participants Bruno Eschli - Head of Investor Relations Teresa Graham - Chief Executive Officer of Roche Pharmaceuticals Levi Garraway - Executive VP, Head of Global Product Development & Chief Medical Officer Aviv Regev - Head of Genentech Research & Early Development (gRED) Alan Hippe - Chief Financial Officer Wendy Cheung Matthew Hellmann Hideki Garren Larry Tsai - Senior VP & Global Head of Immunology Product Development Chris Brittain Manu Chakravarthy - Senior VP and Global Head of Cardiovascular, Renal & Metabolism (CVRM) Product Development Matt Hellman Conference Call Participants Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Sachin Jain - BofA Securities, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division James Gordon - Barclays Bank PLC, Research Division Matthew Weston - UBS Investment Bank, Research Division Graham Glyn Parry - Citigroup Inc., Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Emmanuel Papadakis - Deutsche Bank AG, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Justin Steven Smith - Bernstein Institutional Services LLC, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Urban Fritsche - Zürcher Kantonalbank, Research Division Conversation Bruno Eschli Head of Investor Relations So it's a pleasure again to provide here our annual update. A lot has happened since last year. And we are really excited how things have worked out. I will not waste a lot of time. Just quickly go through the agenda and housekeeping items. So let's start with the morning sessions. First speaker, again, will be our Pharma CEO, Teresa Graham, providing an update on the overall Pharma strategy and life cycle options for our rather fresh and well-established on-market portfolio. The second speaker, as you can see, will be Levi Garraway, our CMO and Head of Global Product Development. Levi will